白细胞介素-1拮抗可降低肥胖个体的皮质醇水平
这项前瞻性干预研究纳入73例BMI≥30 kg/m²且至少合并一项代谢综合征特征的肥胖患者,给予白细胞介素-1受体拮抗剂阿那白滞素(总剂量3×100 mg)。结果显示晨间血清皮质醇、唾液皮质醇、促肾上腺皮质激素、收缩压和心率均显著下降。
要点
- 肥胖患者使用IL-1受体拮抗剂后晨间血清皮质醇从452 nmol/L降至423 nmol/L(95%CI -64至-13.4,P=0.0019)。
- 唾液皮质醇下降-2.8(95%CI -4.4至-1.3,P=0.0007),ACTH下降-2.2(95%CI -4.2至-0.1,P=0.038)。
- 收缩压下降-5.2(95%CI -8.5至-1.8,P=0.0006),心率下降-2.9(95%CI -4.7至-1.0,P=0.0029)。
核心结论
- 伴有代谢综合征特征的肥胖个体中,IL-1拮抗可降低血清皮质醇、唾液皮质醇和ACTH水平,同时降低收缩压和心率。
研究设计与样本
- 前瞻性干预研究,纳入73例肥胖患者(BMI≥30 kg/m²)且至少合并一项代谢综合征特征。
- 干预为给予IL-1受体拮抗剂阿那白滞素(Kineret®),总剂量3×100 mg。
主要发现
- 中位年龄56岁,女性占50.7%,中位BMI为36.3 kg/m²。
- 中位晨间血清皮质醇从基线452 nmol/L降至423 nmol/L,绝对差值为-38.7(95%CI -64至-13.4,P=0.0019)。
- 唾液皮质醇变化为-2.8(95%CI -4.4至-1.3,P=0.0007),ACTH变化为-2.2(95%CI -4.2至-0.1,P=0.038)。
- 收缩压变化为-5.2(95%CI -8.5至-1.8,P=0.0006),心率变化为-2.9(95%CI -4.7至-1.0,P=0.0029)。
关键数值与推荐
- 肥胖定义为BMI≥30 kg/m²,且至少合并一项代谢综合征特征。
- IL-1受体拮抗剂阿那白滞素总剂量为3×100 mg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Increased cortisol levels in obesity may contribute to the associated metabolic syndrome. In obesity, the activated innate immune system leads to increased interleukin (IL)-1β, which is known to stimulate the release of adrenocorticotropin hormone (ACTH). OBJECTIVES: We hypothesized that in obesity IL-1 antagonism would result in downregulation of the hypothalamo-pituitary-adrenal axis, leading to decreased cortisol levels. DESIGN AND PARTICIPANTS: In this prospective intervention study, we included 73 patients with obesity (body mass index [BMI] ≥30 kg/m2) and at least one additional feature of the metabolic syndrome. OUTCOME MEASURES: The primary end point was change in morning cortisol from baseline to after the administration of the IL-1 receptor antagonist (anakinra/Kineret®, total dose 3 × 100 mg). Secondary end points were effects on salivary cortisol and ACTH. RESULTS: Median age was 56 years, 50.7% of patients were female, and median BMI was 36.3 kg/m2. Median morning serum cortisol levels (nmol/L) decreased significantly after IL-1 antagonism [from baseline, 452 to 423; absolute difference, -38.7; 95% confidence interval (CI), -64 to -13.4; P = 0.0019]. Similar effects were found for salivary cortisol levels (-2.8; 95% CI, -4.4 to -1.3; P = 0.0007), ACTH levels (-2.2; 95% CI; -4.2 to -0.1; P = 0.038), systolic blood pressure (-5.2, 95% CI, -8.5 to -1.8; P = 0.0006), and heart rate (-2.9; 95% CI, -4.7 to -1.0; P = 0.0029). CONCLUSION: IL-1 antagonism in obese individuals with features of the metabolic syndrome leads to a decrease in serum cortisol, salivary cortisol, and ACTH levels along with a reduction in systolic blood pressure and heart rate.
引用
- Urwyler SA, Schuetz P, Ebrahimi F, et al. Interleukin-1 Antagonism Decreases Cortisol Levels in Obese Individuals. J Clin Endocrinol Metab. 2017. PMID: 28324042. doi:10.1210/jc.2016-3931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。